Biologics: Targets & Therapy (Apr 2021)
Acrodermatitis Continua of Hallopeau Evolving into Generalized Pustular Psoriasis Following COVID‐19: A Case Report of a Successful Treatment with Infliximab in Combination with Acitretin
Abstract
Dominik Samotij,1 Ewelina Gawron,1 Justyna Szczęch,1 Elżbieta Ostańska,2 Adam Reich1 1Department of Dermatology, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszów, Poland; 2Department of Pathology, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszów, PolandCorrespondence: Adam ReichDepartment of Dermatology, Institute of Medical Sciences, Medical College of Rzeszow University, ul. Fryderyka Szopena 2, Rzeszów, 35-055, PolandTel +48 605076722Fax +48 17 8666294Email [email protected]: The global pandemic of coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is emerging. Various cutaneous manifestations have been observed in patients with SARS-CoV-2 infection, yet exacerbations of psoriasis have been reported sporadically. Acrodermatitis continua of Hallopeau (ACH) is an uncommon, sterile pustular dermatosis involving one or more digits. In some rare cases, ACH may evolve into generalized pustular psoriasis (GPP), which is a severe, and potentially life-threatening, form of psoriasis that manifests itself with widespread eruptions of pustules. We describe the first case of a patient in whom ACH abruptly progressed into GPP during COVID-19. A combination of infliximab and acitretin was used allowing swift clinical improvement.Keywords: psoriasis, pustular psoriasis, biologics, biologic therapy, SARS-CoV-2, coronavirus
